* Stallergenes Greer announces positive top-line results of phase 3 study for pediatric house dust mite-induced allergic rhinitis

* Study achieved its primary efficacy endpoint

* Active group demonstrated a statistically significant difference (p=0.0005) on average adjusted symptom score (AADSS) after one year of treatment versus placebo

* Results will be used to obtain approval from Japan's pharmaceutical and medical device agency (PMDA) in pediatric population. Source text for Eikon: Further company coverage: (Gdynia Newsroom)